RxDoctor Payments Data

Stacey Cantor

Family · West Bloomfield, MINPI 1962837518

Payments from drug & device makers

$611in general payments, 2019–2025

Across 17 payments — averaging $35.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Urovant Sciences Inc$125
  • Boehringer Ingelheim$120
  • Sunovion Pharmaceuticals Inc.$114
  • Novo Nordisk$51
  • Lilly USA, LLC$43
  • Actelion Pharmaceuticals US, Inc.$32
  • plus $126 from 6 others

What the payments were for

  • Food & beverage$611100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$611 in reported general payments places this provider in the 60th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Medicare billing

Part B allowed, 2024
$2,880
Medicare patients
37
Services billed
74

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide17$17,619
Levothyroxine Sodium95$1,171
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$1,072
Carbidopa-LevodopaCarbidopa/Levodopa24$501
Isosorbide Mononitrate14$498
Metoprolol Succinate44$452
Albuterol Sulfate HfaAlbuterol Sulfate15$415
Donepezil Hcl44$404
Amlodipine Besylate69$384
Atorvastatin Calcium46$372
Pramipexole DihydrochloridePramipexole Di-Hcl13$344
Escitalopram Oxalate28$316
Trazodone Hcl43$304
Memantine Hcl19$300
Duloxetine Hcl18$277

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$43$17,61917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,657 family providers in Michigan.

Other family in West Bloomfield

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →